Atlas Trials

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT04484012 · RECRUITING

Trial details

NCT number
NCT04484012
Sponsor
City of Hope Medical Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Start date
2020-12-31
Primary completion
2026-09-02
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.